Doxorubicin Hydrochloride Injection, is available as follows:
Doxorubicin Hydrochloride Injection is a sterile, isotonic solution, available in single-dose polypropylene (CYTOSAFE) vials, and multiple-dose polypropylene (CYTOSAFE) vials:
Unit of Sale | Total Strength/Total Volume (Concentration) |
NDC 0069-3030-20 Carton of 1 Single-dose Vial | 10 mg/5 mL (2 mg/mL) |
NDC 0069-3031-20 Carton of 1 Single-dose Vial | 20 mg/10 mL (2 mg/mL) |
NDC 0069-3032-20 Carton of 1 Single-dose Vial | 50 mg/25 mL (2 mg/mL) |
NDC 0069-3033-20 Carton of 1 Multiple-dose Vial | 150 mg/75 mL (2 mg/mL) |
NDC 0069-3034-20 Carton of 1 Multiple-dose Vial | 200 mg/100 mL (2 mg/mL) |
Retain in carton until contents are used. For single-dose vials, discard unused portion.
Doxorubicin Hydrochloride Injection is a sterile, isotonic solution, available in single-dose ONCO-TAIN glass vials, and multiple-dose ONCO-TAIN glass vials:
Unit of Sale | Total Strength/Total Volume (Concentration) |
NDC 0069-0358-20 Carton of 1 Single-dose Vial | 10 mg/5 mL (2 mg/mL) |
NDC 0069-0277-02 Carton of 1 Single-dose Vial | 20 mg/10 mL (2 mg/mL) |
NDC 0069-0343-02 Carton of 1 Single-dose Vial | 50 mg/25 mL (2 mg/mL) |
NDC 0069-1542-20 Carton of 1 Multiple-dose Vial | 200 mg/100 mL (2 mg/mL) |
ONCO-TAIN is the vial external protection system.
Retain in carton until contents are used. For single-dose ONCO-TAIN glass vials, discard unused portion.
Storage
Store all vials at 2°C to 8°C (36°F to 46°F). Protect from light.
Storage of Doxorubicin Hydrochloride Injection under refrigerated conditions can result in the formation of a gelled product. Place gelled product at room temperature [15ºC to 30ºC (59ºF to 86ºF)] for 2 to 4 hours to return the product to a slightly viscous, mobile solution.
Doxorubicin Hydrochloride Injection, is available as follows:
Doxorubicin Hydrochloride Injection is a sterile, isotonic solution, available in single-dose polypropylene (CYTOSAFE) vials, and multiple-dose polypropylene (CYTOSAFE) vials:
Unit of Sale | Total Strength/Total Volume (Concentration) |
NDC 0069-3030-20 Carton of 1 Single-dose Vial | 10 mg/5 mL (2 mg/mL) |
NDC 0069-3031-20 Carton of 1 Single-dose Vial | 20 mg/10 mL (2 mg/mL) |
NDC 0069-3032-20 Carton of 1 Single-dose Vial | 50 mg/25 mL (2 mg/mL) |
NDC 0069-3033-20 Carton of 1 Multiple-dose Vial | 150 mg/75 mL (2 mg/mL) |
NDC 0069-3034-20 Carton of 1 Multiple-dose Vial | 200 mg/100 mL (2 mg/mL) |
Retain in carton until contents are used. For single-dose vials, discard unused portion.
Doxorubicin Hydrochloride Injection is a sterile, isotonic solution, available in single-dose ONCO-TAIN glass vials, and multiple-dose ONCO-TAIN glass vials:
Unit of Sale | Total Strength/Total Volume (Concentration) |
NDC 0069-0358-20 Carton of 1 Single-dose Vial | 10 mg/5 mL (2 mg/mL) |
NDC 0069-0277-02 Carton of 1 Single-dose Vial | 20 mg/10 mL (2 mg/mL) |
NDC 0069-0343-02 Carton of 1 Single-dose Vial | 50 mg/25 mL (2 mg/mL) |
NDC 0069-1542-20 Carton of 1 Multiple-dose Vial | 200 mg/100 mL (2 mg/mL) |
ONCO-TAIN is the vial external protection system.
Retain in carton until contents are used. For single-dose ONCO-TAIN glass vials, discard unused portion.
Storage
Store all vials at 2°C to 8°C (36°F to 46°F). Protect from light.
Storage of Doxorubicin Hydrochloride Injection under refrigerated conditions can result in the formation of a gelled product. Place gelled product at room temperature [15ºC to 30ºC (59ºF to 86ºF)] for 2 to 4 hours to return the product to a slightly viscous, mobile solution.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.